Peter Keeling, CEO, Diaceutics
The Irish company helping patients through better diagnostic testing has today announced a collaboration with computer hardware manufacturer Lenovo and Intel.
This collaboration will allow Diaceutics leverage their large proprietary database of patient testing data.
The company hopes this data can be used to help improve diagnosis, treatment and outcomes for patients with similar characteristics through the implementation of artificial intelligence (AI).
Lenovo‘s ThinkStation P920, powered by the Intel Xeon Scalable Processors and complex testing data from hundreds of clinical laboratories, will help Diaceutics get the right medicine to the right people at the right time by classifying patient groups and disease patterns.
The machine learning system will organise information which could mean that at-risk patients can be identified, diagnosed and treated much faster.
With 78,000 cancer patients not properly tested each year in the US and denied access to lifesaving medication, this new initiative could transform personalised medicine.
The CEO of Diaceutics, Peter Keeling, said: “Artificial intelligence can make a very strong and positive impact on precision medicine and we are excited to be moving the boundaries with this highly-innovative technology.
“We can now look at data in a novel way. No longer will we only be making decisions based on diagnostic data. Artificial intelligence allows us to look at the complete patient journey from initial testing and diagnosis, and on to the ultimate treatment. The result will be significantly better patient testing and likely improved patient outcomes, such as longer cancer survivorship rates.
“This collaboration is a major step in our mission to help patients, by helping them find the right precision medicine at the right time. We are using artificial intelligence to enable the world to unlock the true life-changing promise of precision medicine.”